EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey Yasushi Yatabe, MD, PhD, Keith M. Kerr, FRCPath,

Slides:

Advertisements

Similar presentations

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Advertisements

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer:

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Epidermal Growth Factor Receptor Mutations in 510 Finnish Non–Small-Cell Lung Cancer Patients Satu Mäki-Nevala, MSc, Mikko Rönty, MD, Mike Morel, MBiolSci,

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors Su Jin Lee, MD, Jung-Il Lee,

Comparison of the Yield of Different Diagnostic Procedures for Cellular Differentiation and Genetic Profiling of Non–Small-Cell Lung Cancer Amr S. Albanna,

Pulmonary Metastasectomy: A Survey of Current Practice Amongst Members of the European Society of Thoracic Surgeons Eveline Internullo, MD, Stephen D.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status Jean-Yves Douillard,

Epidermal Growth Factor Receptor Mutation and p53 Overexpression during the Multistage Progression of Small Adenocarcinoma of the Lung Seol Bong Yoo,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

Activity of Gefitinib in a Non–Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations Alessandro Morabito, MD, Raffaele Costanzo,

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation Bhumsuk.

First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally.

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

CtDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study Martin Reck, MD, PhD, Koichi Hagiwara,

Carolyn J. Shiau, MD, FRCPC, Jesse P

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Erratum Journal of Thoracic Oncology

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q Satoshi Watanabe, MD, PhD, Yuji Minegishi,

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Mitotic Inhibitors Journal of Thoracic Oncology

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung.

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns Kuo-Hsuan Hsu, MD, Kun-Chieh Chen, MD,

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer Nicola Normanno, MD, Carmine.

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

PS01.37: Comparison Between Sanger Sequencing and ARMS qPCR Method for EGFR Gene Mutation Detection of Non–Small Cell Lung Cancer Jiexia Zhang, Xiaoshun.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey Yasushi Yatabe, MD, PhD, Keith M. Kerr, FRCPath,

A Review of First-Line Treatment for Small-cell Lung Cancer

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey Yasushi Yatabe, MD, PhD, Keith M. Kerr, FRCPath, Ahmad Utomo, PhD, Pathmanathan Rajadurai, MD, FRCPA, Van Khanh Tran, MD, PhD, Xiang Du, MD, PhD, Teh-Ying Chou, MD, PhD, Ma. Luisa D. Enriquez, PhD, Geon Kook Lee, MD, PhD, Jabed Iqbal, MD, PhD, Shanop Shuangshoti, MD, Jin-Haeng Chung, MD, PhD, Koichi Hagiwara, MD, PhD, Zhiyong Liang, MD, PhD, Nicola Normanno, MD, Keunchil Park, MD, PhD, Shinichi Toyooka, MD, PhD, Chun-Ming Tsai, MD, Paul Waring, FRCPA, Li Zhang, MD, Rose McCormack, PhD, Marianne Ratcliffe, PhD, Yohji Itoh, PhD, Masatoshi Sugeno, PhD, Tony Mok, MD Journal of Thoracic Oncology Volume 10, Issue 3, Pages 438-445 (March 2015) DOI: 10.1097/JTO.0000000000000422 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Nature of samples tested for EGFR mutations at participating sites. No data were available for Malaysia. †Data from responses to question: “(Amongst NSCLC cases tested for EGFR mutations in your laboratory, what is the) number of surgical specimen samples tested?” ‡Data from responses to question: “(Amongst NSCLC cases tested for EGFR mutations in your laboratory, what is the) number of biopsy and/or cytology samples tested?” §Data from responses to question: “How many samples tested for EGFR mutation during 2011 were cytology samples?” Proportions of biopsy and/or cytology samples and of surgical specimens were calculated using data from only those sites that provided answers to both questions on “NSCLC samples that were biopsy and/or cytology samples” and “NSCLC samples that were surgical specimens.” The proportions of cytology samples were calculated using data from the sites that provided answers to all three questions, i.e., on “NSCLC samples that were biopsy and/or cytology samples,” “NSCLC samples that were surgical specimens” and “NSCLC samples that were cytology samples.” EGFR, epidermal growth factor receptor; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2015 10, 438-445DOI: (10.1097/JTO.0000000000000422) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Most commonly used EGFR mutation testing methods for tissue and cytology samples across Asia, determined as a percentage of participating sites. Cobas EGFR Mutation Test (Roche) was included in the survey as an option, but was not selected by any site as the most commonly used test. †Two sites (5.0%) had missing data or did not test cytology samples. ‡Nature of methods not ascertained. EGFR, epidermal growth factor receptor. Journal of Thoracic Oncology 2015 10, 438-445DOI: (10.1097/JTO.0000000000000422) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Information about EGFR mutation testing sites that participated in the survey. A, Type of laboratory; B, accreditation; and C, participation in QA schemes amongst participating laboratories. EGFR, epidermal growth factor receptor; QA, quality assurance. Journal of Thoracic Oncology 2015 10, 438-445DOI: (10.1097/JTO.0000000000000422) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions